• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Pulmonology

Latest News

The approval of nerandomilast was based on FIBRONEER-ILD data. | Image credit: wladimir1804 - stock.adobe.com
FDA Approves Nerandomilast for Progressive Pulmonary Fibrosis

December 19th 2025

The approval was based on the pivotal phase 3 FIBRONEER-ILD trial, in which nerandomilast slowed lung function decline in PPF and had similar discontinuation rates to placebo.

ICYMI: Highlights From ATS 2025
ICYMI: Highlights From ATS 2025

December 18th 2025

The subgroup analysis aligned with the broader FIBRONEER-IPF trial. | Image credit: Ahmad - stock.adobe.com
Nerandomilast Shown Safe, Effective in IPF Among US FIBRONEER-IPF Subgroup

October 31st 2025

Although mortality rates have generally improved over the last 2 decades, demographic and geographic inequities remain. | Image credit: Kiattisak - stock.adobe.com
Disparities in Pneumonia and Fibrosis Mortality Persist Across the US

October 31st 2025

FDA approval | Image Credit: ©Olivier Le Moal-stock.adobe.com
FDA Expands Sotatercept Indication for PAH

October 27th 2025

More News

© 2025 MJH Life Sciences
AJMC®
All rights reserved.